PT  - JOURNAL ARTICLE
AU  - Kim, Chaelin
AU  - Holm, Marianne
AU  - Frost, Isabel
AU  - Hasso-Agopsowicz, Mateusz
AU  - Abbas, Kaja
TI  - Global and regional burden of attributable and associated bacterial antimicrobial resistance avertable by vaccination: modelling study
AID  - 10.1101/2022.05.08.22274821
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.05.08.22274821
4099  - http://medrxiv.org/content/early/2022/11/28/2022.05.08.22274821.short
4100  - http://medrxiv.org/content/early/2022/11/28/2022.05.08.22274821.full
AB  - Introduction Antimicrobial resistance (AMR) is a global health threat with 1.27 million and 4.95 million deaths attributable to and associated with bacterial AMR respectively in 2019. Our aim is to estimate the vaccine avertable bacterial AMR burden based on existing and future vaccines at the regional and global levels by pathogen and infectious syndromes.Methods We developed a static proportional impact model to estimate the vaccination impact on 15 bacterial pathogens in terms of reduction in age-specific AMR burden estimates for 2019 from the Global Research on Antimicrobial Resistance project in direct proportion to efficacy, coverage, target population for protection, and duration of protection of existing and future vaccines.Results In the baseline scenario for vaccination of primary age-groups against 15 pathogens, we estimated vaccine-avertable AMR burden of 0.51 (95% UI: 0.49 - 0.54) million deaths and 28 (27 - 29)million DALYs associated with bacterial AMR, and 0.15 (0.14 - 0.17) million deaths and 7.6 (7.1 - 8.0) million DALYs attributable to AMR globally in 2019. In the high-potential scenario for vaccination of additional age groups against 7 pathogens, we estimated vaccine-avertable AMR burden of an additional 1.2 (1.18 - 1.23) million deaths and 37 (36 - 39) million DALYs associated with AMR, and 0.33 (0.32 - 0.34) million deaths and 10 (9.8 - 11) million DALYs attributable to AMR globally in 2019.Conclusion The AMR burden avertable by vaccination in 2019 was highest for the WHO Africa and South-East Asia regions, for lower respiratory infections, tuberculosis, and bloodstream infections by infectious syndromes, and for Mycobacterium tuberculosis and Streptococcus pneumoniae by pathogen. Increased coverage of existing vaccines and development of new vaccines are effective means to reduce AMR, and this evidence should inform the full value of vaccine assessments.What is already known on this topicThere is some evidence on the impact of vaccines against Haemophilus influenzae type b, rotavirus, Streptococcus pneumoniae, Salmonella Typhi and influenza on antimicrobial resistance (AMR) in specific settings.What this study addsTo our knowledge, this is the first study to estimate attributable and associated bacterial AMR burden avertable by vaccination against 15 bacterial pathogens for a combined set of existing and new vaccines in the pipeline by pathogen, infectious syndrome, and region.The AMR burden avertable by vaccination in 2019 was highest for the WHO Africa and South-East Asia regions, for lower respiratory infections, tuberculosis, and bloodstream infections by infectious syndromes, and for Mycobacterium tuberculosis and Streptococcus pneumoniae by pathogen.How this study might affect research, practice or policyOur model-based projections facilitate evidence-based decision-making for scaling up of existing vaccines to regions in most need with higher AMR burden and prioritise development of new vaccines with high potential for lowering AMR burden by pathogen, infectious syndrome, and region.Our study contributes to the WHO-led value attribution framework for vaccines against antimicrobial resistance, and specifically to the criterion focused on vaccine averted AMR health burden.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by the Bill & Melinda Gates Foundation (INV-006816). The funders were not involved in the study design, data collection, data analysis, data interpretation, writing of the report, and the decision to submit for publication. All authors had full access to all the data in the study and final responsibility for the decision to submit for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:London School of Hygiene & Tropical MedicineI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.